These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18792871)

  • 1. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
    Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
    Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
    Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
    Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
    Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
    Kato T; Inoue T; Node K
    Cardiovasc Diabetol; 2010 Mar; 9():12. PubMed ID: 20334663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
    Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
    Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 10. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
    González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
    J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
    Miura K; Kitahara Y; Yamagishi S
    Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.